APOB and obesity due to melanocortin 4 receptor deficiency: In the obesity trial, at 36 weeks, ApoB decreases observed with orforglipron ranged from − 11.4 to − 13.4%, statistically different from the effect of placebo (− 2.7%; Fig. 3, Supplemental Table 2).